/C O R R E C T I O N -- Bayer Pharmaceuticals Corporation/
May 19 2004 - 11:46AM
PR Newswire (US)
/C O R R E C T I O N -- Bayer Pharmaceuticals Corporation/ In the
news release, FDA Approves Avelox(R) (moxifloxacin HCI) for
Community Acquired Pneumonia Due to Multi-Drug Resistant
Streptococcus pneumoniae, issued earlier today by Bayer
Pharmaceuticals Corporation over PR Newswire, we are advised by a
representative of the company that the third paragraph, last
sentence, should read "... rates of 93% to 100%" rather than "...
rates of 93% to 95%" as originally issued inadvertently. PRNewswire
-- May 19 DATASOURCE: Bayer Pharmaceuticals Corporation
Copyright